ZnPc-PEG2-VH032
ZnPc-PEG2-VH032 is a VHL-pathway-dependent photodegradation targeting chimera (PDTAC) and cytotoxic agent. ZnPc-PEG2-VH032 (HY-120217) binds to the VHL ligand domain, and then specifically degrades VHL under light irradiation, a process independent of non-specific ROS-mediated protein damage. ZnPc-PEG2-VH032 uses Zinc phthalocyanine (HY-19204) as a photosensitizer, and generates ROS via type I and type II photodynamic pathways under 680 nm LED irradiation. On one hand, it targets and degrades the bound VHL protein through ROS; on the other hand, it exerts direct photodynamic cytotoxicity. Meanwhile, the degradation of VHL downregulates the phosphorylation level of CDK2/4, induces cell cycle arrest in tumor cells, further enhances the sensitivity of tumor cells to oxidative damage caused by ROS, and achieves a synergistic anti-tumor effect. ZnPc-PEG2-VH032 exerts significant in vivo efficacy in an orthotopic mouse model of non-muscle invasive bladder cancer (NMIBC).
(Pink: Reactive Oxygen Species (ROS) ligand (HY-19204); Blue: VHL ligand (HY-120217); Black: linker).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C68H61N13O8SZn
- Masse moléculaire:1285.74
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform PROTACs
More
Activité biologique
|
VHL |
CDK2 |
ZnPc-PEG2-VH032 binds with high affinity to VHL protein, forming hydrogen bonds with specific residues and interacting with additional surrounding residues to stabilize the complex[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice (female, 16-20 g weight, orthotopic non-muscle-invasive bladder cancer model via mCherry-MB-49 bladder carcinoma cell implantation with silver nitrate etching)[1]
-
Dosage:0.625 mg/kg
-
Administration:bladder instillation; days 1, 3, 5, 8, 10; followed by 10 minutes of 680 nm LED light exposure (12 J/cm2) 2 hours post-administration
-
Result:Showed no antitumor activity under non-illuminated conditions (bladder mCherry fluorescence intensity similar to PBS control).
Reduced bladder mCherry fluorescence intensity to nearly absent levels under light-treated conditions, matching efficacy of positive control mitomycin C.
Achieved near-complete elimination of tumor structures in the bladder while preserving normal bladder tissue architecture.
Maintained stable mouse body weights throughout the treatment cycle.
Chemical Information
-
Masse moléculaire 1285.74
-
Formule C68H61N13O8SZn
-
SMILES
O=C(NCCOCCOCCC(N[C@@H](C(C)(C)C)C(N1C[C@H](O)C[C@H]1C(NCC2=CC=C(C3=C(C)N=CS3)C=C2)=O)=O)=O)C(C=C4)=CC=C4OC5=CC=C6C7=NC8=C9C(C=CC=C9)=C%10[N-]8[Zn+2]%11([N]7=C(C6=C5)N=C%12C%13=CC=CC=C%14%13)[N-]%12C%14=NC(C%15=CC=CC=C%16%15)=[N]%11C%16=N%10
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)